CD274 and non-small cell lung carcinoma: There is some research showing that first-line nivolumab combination with ipilimumab prolonged progression-free survival (PFS) compared to conventional chemotherapy for non-small cell lung carcinoma (NSCLC) patients with a high mutational burden, regardless of PD-L1 expression level [9].